154
Views
18
CrossRef citations to date
0
Altmetric
Original Article

Long-term endometrial and breast safety of a specific, standardized soy extract

, , , , &
Pages 368-375 | Received 28 Sep 2009, Accepted 18 Jan 2010, Published online: 10 Apr 2010
 

Abstract

Objective To assess the effects of an oral soy isoflavone extract (Phytosoya®) on endometrium and breast in postmenopausal women treated for 3 years.

Methods A total of 395 postmenopausal women were included in this international prospective, open-label study. The number of patients who completed the 3-year study was 197. The women were treated for 3 years with a specific, standardized soy isoflavone extract (total 70 mg/day). Endometrial biopsy, transvaginal ultrasonography and mammography were performed before and after 3 years of treatment.

Results No case of hyperplasia/cancer was diagnosed among the 192 interpretable biopsies at 3 years. Only one case of simple hyperplasia was diagnosed among 197 post-baseline interpretable biopsies. The endometrial safety of this extract has been demonstrated (point estimate 0.5%). There was no statistically significant change in endometrial thickness after 3 years (98.4% inactive or atrophic and 0.3% proliferative endometrium at 1 year). Mammography results showed no notable change from baseline. No patient in any set developed an ACR classification of 4 or 5 after 3 years of treatment. The global safety was rated as either ‘excellent’ or ‘good’ by 99.1% of investigators and 99.0% of patients after 3 years of treatment. The adverse events were as follows: eight patients had metrorrhagia and seven patients had at least one breast adverse event: three patients had ‘breast pain’, two patients reported ‘breast tenderness’ and two patients had ‘hypertrophic breast’ (most of them were possibly treatment-related).

Conclusions As no case of hyperplasia was diagnosed among the 301 interpretable biopsies at 1 year and there was only one case of simple hyperplasia in the 197 post-baseline biopsies at 3 years, the endometrial safety of this extract has been demonstrated. Furthermore, as demonstrated by the lack of change in endometrial thickness associated with the histologic results, we suggest that this extract does not exert a mitogenic effect on the endometrium. These results suggest that daily administration of 70 mg of a specific, standardized isoflavone extract for 3 years could be a safe treatment for both endometrium and breast.

Conflict of interest  S. Palacios has been a symposium speaker or advisory board member for several companies, including Bayer-Schering, Novo Nordisk, Servier, Lilly, Daiichi-Sankyo, Sanofi-Aventis, MSD and Procter and Gamble. He also receives research grants and/or consulting fees from the following companies: Wyeth, Servier, Lilly, Daiichi-Sankyo, Amgen, Arkochim and Bayer-Schering. L. Aubert, at the time of the clinical trial, was Clinical Project Manager at Arkopharma Laboratories; P. Chantre, at the time of the clinical trial, was Head of Clinical Development at Arkopharma Laboratories; B. Pornel, F. Vázquez and P. Marès declare no conflict of interest.

Source of funding  This work was supported by Arkopharma Pharmaceutical Laboratories.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 277.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.